Phase I/II Study of Vaccination Comprising α-1,3-Galactosyltransferase-Expressing Allogeneic Tumor Cells (HyperAcute™ Lung Cancer Vaccine) in Patients With Advanced Refractory or Recurrent Non-Small Cell Lung Cancer (Phase I Is Closed to Accrual as of 10/06/09)

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Alternate Title

Vaccine Therapy in Treating Patients With Advanced Refractory or Recurrent Non-Small Cell Lung Cancer

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase II, Phase IBiomarker/Laboratory analysis, TreatmentClosed18 and overNCI, Pharmaceutical / IndustryNCI-04-C-0049
NLGC-0101, NCT00075790

Special Category: NCI Web site featured trial



  1. Determine the side effects, dose-limiting toxicity, and maximum tolerated dose of vaccination comprising α-1,3-galactosyltransferase-expressing allogeneic tumor cells (HyperAcute™ Lung Cancer Vaccine) in patients with advanced refractory or recurrent non-small cell lung cancer. (phase I, completed 10/06/09)
  2. Determine tumor response rate in patients treated with this vaccine. (phase II)


  1. Determine the immunological response in patients treated with this vaccine. (phase II)
  2. Determine the survival distribution and duration of response in patients treated with this vaccine. (phase II)

Entry Criteria

Disease Characteristics:

  • Histologically confirmed non-small cell lung cancer (NSCLC)
    • The following cellular subtypes are eligible:
      • Bronchoalveolar (papillary) carcinoma
      • Squamous cell (epidermoid)
      • Adenocarcinoma
      • Large cell anaplastic
      • Mixed hystologie of NSCLC (i.e., adenosquamous) allowed
        • No mixed NSCLC and small cell lung carcinoma or variant large and small cell lung carcinoma
    • Must meet criteria for 1 of the following stages:
      • Stage IV (any T, any N, M1)
      • Metastatic
      • Progressive, recurrent, or refractory
  • Patients should have:
    • NSCLC sites that are accessible to needle, punch, or other limited biopsy
      • Sites may include skin and soft tissue metastases, adrenal gland metastases, or peripheral lymph nodes (supraclavicular, axillary, or inquinal)
    • A pulmonary lesion at low-risk for biopsy and/or complications defined as lesions >1.5 cm surrounded by aerated lung, pleural-based masses >1.5 cm and lesions not associated with a major pulmonary vessel, or other disease sites that may undergo biopsy with minimal discomfort and risk to the patient (these sites are optional)
  • Measurable or nonmeasurable disease
  • No active CNS metastases or carcinomatous meningitis
  • Ineligible for other curative intent treatment (e.g., surgical resection)

Prior/Concurrent Therapy:

    Biologic therapy

  • See Chemotherapy
  • At least 4 weeks since prior biological or targeted therapy


  • See Disease Characteristics
  • Prior surgery, radiotherapy, immunotherapy, and/or chemotherapy regimens for NSCLC, including neoadjuvant and adjuvant treatment, allowed
    • Preoperative neoadjuvant and postoperative (within 12 weeks after surgery) adjuvant chemotherapy with the same agent is considered 1 prior regimen
    • Gefitinib, erlotinib, monoclonal antibodies, or other small molecule or targeted therapies will be considered as prior chemotherapy or immunotherapy
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

    Endocrine therapy

  • No concurrent systemic corticosteroids
    • Concurrent inhaled or topical corticosteroids are allowed
  • No concurrent replacement therapy for hypoadrenalism


  • At least 4 weeks since prior radiotherapy


  • No prior organ transplantation
  • At least 4 weeks since prior major surgery


  • Recovered from all prior therapy (except alopecia and fatigue)
  • More than 1 week since prior antibiotics
  • No concurrent tacrolimus
  • No other concurrent immunosuppressive therapy

Patient Characteristics:


  • 18 and over

    Performance status

  • ECOG 0-2

    Life expectancy

  • At least 4 months


  • Hemoglobin ≥ 10.0 g/dL
  • Absolute granulocyte count ≥ 1,000/mm3
  • Platelet count ≥ 100,000/mm3
  • Absolute lymphocyte count ≥ 475/mm3


  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • ALT and AST ≤ 2.5 times ULN
  • Albumin ≥ 3.0 g/dL
  • Hepatitis B and C negative
  • No liver cirrhosis


  • Creatinine ≤ 1.5 times ULN


  • Creatinine clearance ≥ 50 mL/min
  • No hypercalcemia > 2.9 mmol/L that is unresponsive to standard therapy (e.g., IV hydration, diuretics, calcitonin, and/or bisphosphonate therapy)


  • No significant or uncontrolled congestive heart failure
  • No myocardial infarction within the past 6 months
  • No significant ventricular arrhythmias within the past 6 months


  • No significant pulmonary dysfunction
  • A history of asthma or mild active asthma is allowed


  • HIV negative
  • No active infection or unexplained fever (i.e., temperature > 38.1°C)
  • No autoimmune disease (e.g., systemic lupus erythematosus or active rheumatoid arthritis)
  • No known allergy to any component of the study drug or cell lines from which it was derived


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 1 month after study participation
  • Willing to undergo tumor core needle biopsy, punch or other similar biopsy pre-vaccination and again post-vaccination
  • No other malignancy within the past 5 years except malignancies for which the probability of recurrence is less than 5%, curatively treated squamous cell or basal cell skin cancer, or carcinoma in situ of the cervix
  • No other serious medical condition that would limit life expectancy to less than 2 years
  • No other medical or psychiatric condition (e.g., untreated schizophrenia or other significant cognitive impairment) that would preclude study participation

Expected Enrollment


A total of 54 patients will be accrued for this study within 3-4 years.


Primary Outcome(s)

Adverse effects, dose-limiting toxicity, and maximum tolerated dose as measured by CTCAE v.3 and RECIST criteria pre-treatment, during study treatment, and 6 months after completion of study treatment (phase I)
Tumor response rate as measured by CTCAE v.3 and RECIST criteria pre-treatment, during study treatment, and 6 months after completion of study treatment (phase II)

Secondary Outcome(s)

Immunological response as measured by an assay of serum anti-alpha-gal titers and enzyme-linked immunospot assay for interferon-gamma and interleukin-5 pre-treatment and at 6 months after completion of study treatment


This is a non-randomized, open-label, dose-escalation followed by a phase II study. (Phase I is closed to accrual as of 10/06/09)

Patients receive vaccination comprising α-1,3-galactosyltransferase-expressing allogeneic tumor cells (HyperAcute™ Lung Cancer Vaccine [HAL]) intradermally on days 1, 29, 57, and 85 in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of HAL vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 6 patients receive treatment at the MTD.

Some patients undergo tumor tissue biopsies at baseline and after 3 vaccinations for cellular immune response by IHC assays. Blood samples are also collected at baseline and periodically during study for immune response by ELISA, total immunophenotyping by FACS, and Western Blot.

Quality of life is assessed at baseline; days 29, 57, 85, 99, and 127; and then every 2 months for 1 year.

Patients are followed monthly for 1 year, every 3 months for 2 years, and then annually for 15 years.

Published Results

Morris JC, Janik JE, Vahanian N, et al.: A phase I study of antitumor vaccination using genetically modified tumor cells expressing (1,3) galactosyltransferase in patients with refractory or recurrent non-small cell lung cancer (NSCLC): preliminary results. [Abstract] American Society of Gene Therapy: 8th Annual Meeting, 1-5 June, 2005, St. Louis, MO. A-1133, 2005.

Morris JC, Vahanian N, Janik JE, et al.: Phase I study of an antitumor vaccination using α(1,3) galactosyltransferase expressing allogeneic tumor cells in patients (Pts) with refractory or recurrent non-small cell lung cancer (NSCLC). [Abstract] J Clin Oncol 23 (Suppl 16): A-2586, 187s, 2005.

Trial Contact Information

Trial Lead Organizations

NCI - Center for Cancer Research

Giuseppe Giaccone, MD, PhD, Protocol chair (Contact information may not be current)
Ph: 301-496-4916
Charles Joseph Link, MD, Protocol co-chair
Ph: 515-296-5555

Related Information

Web site for additional information
Featured trial article

Registry Information

Official TitleA Phase I/II Study Of An Antitumor Vaccination Using α(1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells In Patients With Refractory Or Recurrent Non-Small Cell Lung Cancer
Trial Start Date2003-12-22
Trial Completion Date2010-12-01 (estimated)
Registered in ClinicalTrials.govNCT00075790
Date Submitted to PDQ2003-12-05
Information Last Verified2009-06-03

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.